Introduction: Phenotyping allergic rhinitis (AR) by immunoglobulin E (IgE) sensitivity and comorbidities may help characterize AR and provide a framework for treatment decisions. Methods: This prospective, noninterventional study evaluated the effectiveness of MP-AzeFlu (azelastine hydrochloride plus fluticasone propionate intranasal spray formulation) across AR phenotypes. Patients with moderate-to-­severe seasonal or perennial AR for whom MP-AzeFlu was prescribed were enrolled. AR subpopulations (ARPs) were assigned based on the classification of IgE response and comorbidities. AR symptoms over the previous 24 h were documented using an AR visual analog scale (AR-VAS), with ratings from “not at all bothersome” (0 mm) to “extremely bothersome” (100 mm), at the inclusion visit and on days 1, 3, 7, and the last day of the study (approximately day 14). AR quality-of-life measures were recorded using a VAS. Results: A total of 1,103 patients with AR were included. Mean baseline AR-VAS scores ranged from 70.3 to 75.1 mm (severe) across ARPs. In the overall population, 86.6% of patients responded to treatment (AR-VAS score #x3c;50 mm on ≥1 days). In the ARPs, response rates ranged from 79.3 to 89.6%. Mean reduction in AR-VAS scores ranged from 47.9 to 40.9 mm, a decrease from severe to mild across all ARPs. Quality-of-life VAS scores were similarly reduced in the total population and ARPs. Discussion/Conclusion: MP-AzeFlu treatment reduced VAS severity and quality-of-life scores from baseline in the total population and ARPs, supporting MP-AzeFlu as an effective treatment for all patients with moderate-to-severe AR, regardless of AR phenotype or comorbidities.
Int Arch Allergy Immunol

中文翻译：

---

在现实生活研究中，特定免疫球蛋白E反应和合并症对MP-AzeFlu有效性的影响。

简介：通过免疫球蛋白E（IgE）敏感性和合并症对过敏性鼻炎（AR）进行表型分析可能有助于AR的特征化，并为治疗决策提供框架。方法：这项前瞻性，非干预性研究评估了MP-AzeFlu（氮卓斯汀盐酸盐加氟替卡松丙酸酯鼻腔喷雾剂）在AR表型中的有效性。入选了中度至重度的季节性或常年性AR患者，并为其开具MP-AzeFlu处方。根据IgE反应和合并症的分类来分配AR亚群（ARP）。在过去的24小时内，使用AR视觉模拟量表（AR-VAS）记录了AR症状，在纳入访问及以后，其评分从“完全不烦恼”（0 mm）到“极度烦恼”（100 mm）。第1、3、7天以及研究的最后一天（大约第14天）。使用VAS记录AR生活质量测度。结果：总共纳入了1,103例AR患者。ARP的平均基线AR-VAS评分范围为70.3至75.1 mm（严重）。在总体人群中，有86.6％的患者对治疗有反应（AR-VAS评分＃x3c；≥1天时50 mm）。在ARP中，响应率介于79.3至89.6％之间。AR-VAS评分的平均降低范围为47.9至40.9 mm，在所有ARP中均从严重降低为轻度。生活质量的VAS分数在总人口和ARPs中同样降低。讨论/结论： MP-AzeFlu治疗降低了总人群和ARPs的VAS严重性和生活质量得分，与基线相比，支持MP-AzeFlu作为所有中重度AR患者的有效治疗方法，无论AR表型如何或合并症。
Int Arch过敏免疫